← ANALYST RATINGS · TIPRANKS
Emergent Biosolutions (EBS): analyst forecast and price target
Analyst consensus
Hold1 Buy0 Hold1 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $10.00, the highest $10.00, the lowest $10.00. The average is +56.7% from the last price of $6.38.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $7.00 → $7.50+7.1% | Hold | +17.6% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $7.00 → $7.50+7.1% | Hold | +17.6% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $7.00 → $7.50+7.1% | Hold | +17.6% | Reiterated | 06.10.26on TipRanks 01:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $6.00 → $7.00+16.7% | Hold | +9.7% | Reiterated | 18.09.26on TipRanks 03:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $6.00 → $7.00+16.7% | Hold | +9.7% | Reiterated | 18.09.26on TipRanks 03:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $6.00 → $7.00+16.7% | Hold | +9.7% | Reiterated | 18.09.26on TipRanks 03:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $10.00 | Buy | +56.7% | Reiterated | 09.09.26on TipRanks 06:55 | −4.9%next day +3.9% · 5 days +19.9% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | — | Sell | — | Initiated | 21.08.26on TipRanks 06:43 | +5.0%next day +2.3% · 5 days +15.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Emergent Biosolutions
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.00 at a price of $6.60 (+51.5%); now: $10.00 at $6.38 (+56.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 1 | 2 | 2 |
| Buy | 4 | 3 | 2 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
Earnings and sales forecast
Next report: 02.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.39 (from $-0.41 to $-0.37). Last quarter: $0.60.
Sales
Next quarter’s sales estimate — $123M (from $118M to $129M). Last quarter: $234M.
Best top-analyst consensus in the sector · Healthcare
About Emergent Biosolutions
- CEO: Joseph C. Papa Jr.
- Employees: 900
- 400 Professional Drive, Gaithersburg, MD, 20879, US
- www.emergentbiosolutions.com
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Data from the stock’s TipRanks forecast page, read 153 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗